HBV DNA整合诱发肝细胞癌分子机制的研究进展

摘要/Abstract

摘要： 肝细胞癌(HCC)是一种起源于肝细胞的恶性肿瘤,其病因尚未完全明确,目前已知乙型肝炎病毒(HBV)感染是其主要的病因。早期临床症状不明显,晚期主要以肝区疼痛、黄疸、进行性消瘦为特征,严重时甚至可以出现上消化道出血、肝性脑病。HBV整合是HBV不断将自身脱氧核糖核酸(DNA)整合入宿主基因组中,并且在一定程度上起到促癌的作用,在乙型肝炎相关HCC中,整合子可导致与细胞周期和生命活动有关的癌症相关基因上调,诱导染色体不稳定,产生病毒癌蛋白(HBX),导致其他(可能致癌的)病毒-人转录本融合(HBV-LINEⅠ)和激活端粒酶,这些机制可能单独或协同发挥作用,导致HCC的发生。本文就HBV DNA整合在乙型肝炎相关HCC中的作用机制及临床意义进行综述,有助于改善和提高现行的抗病毒治疗策略,提前采取有效措施,降低HCC的发生率。

金超, 李小婷, 刘宏宇, 蔡采莲, 王可杉, 韦艳春, 苏明华. HBV DNA整合诱发肝细胞癌分子机制的研究进展[J]. 肝脏, 2024, 29(6): 731-735.

/ 推荐

参考文献

[1] Hsu Y-C,Huang D Q,Nguyen M H. Global burden of hepatitis B virus: current status, missed opportunities and a call for action[J]. Nat Rev Gastroenterol Hepatol, 2023,20(8):524-537.
[2] 周召,阿卜杜热西提·阿卜来提,顾智强. 尽早启动抗病毒治疗降低慢性HBV感染者肝细胞癌发生风险[J]. 临床肝胆病杂志, 2023, 39(1): 31-36.
[3] Tang K W,Larsson E. Tumour virology in the era of high-throughput genomics[J]. Philos Trans R Soc Lond B Biol Sci, 2017, 372(1732):20160265.
[4] Peneau C,Imbeaud S,La Bella T. Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma[J]. Gut, 2022, 71(3): 616-626.
[5] Tu T,Budzinska M A,Vondran F W R. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles[J]. J Virol, 2018, 92(11):e02007-e02017.
[6] Sze K M F,Ho D W H,Chiu Y T. Hepatitis B virus–telomerase reverse transcriptase promoter integration harnesses host ELF4, resulting in telomerase reverse transcriptase gene transcription in hepatocellular carcinoma[J]. Hepatology, 2020, 73(1): 23-40.
[7] Sze K M,Chu G K,Lee J M. C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma[J]. Hepatology, 2013, 57(1): 131-139.
[8] Jang J W,Kim H S,Kim J S. Distinct patterns of HBV integration and TERT alterations between in tumor and non-tumor tissue in patients with hepatocellular carcinoma[J]. Int J Mol Sci, 2021, 22(13):7056.
[9] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
[10] Terrault N A,Lok A S F,McMahon B J. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599.
[11] Sarin S K,Kumar M,Lau G K. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98.
[12] Kang C K,Brennan P N,Dillon J F. How to effectively monitor aging patients with chronic hepatitis B: a review[J]. Clin Interv Aging, 2022, 17: 1811-1820.
[13] Jiang S,Yang Z,Li W. Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis[J]. PLoS One, 2012, 7(9): e40363.
[14] Ringelhan M,McKeating J A,Protzer U. Viral hepatitis and liver cancer[J]. Philos Trans R Soc Lond B Biol Sci, 2017, 372(1732):20160274.
[15] Buendia M A,Neuveut C. Hepatocellular carcinoma[J]. Cold Spring Harb Perspect Med, 2015, 5(2): a021444.
[16] Ruan P,Dai X,Sun J. Different types of viral host junction found in HBV integration breakpoints in HBV infected patients[J]. Mol Med Rep, 2019, 19(2): 1410-1416.
[17] Yang X,Wu L,Lin J. Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent normal liver tissue[J]. Int J Cancer, 2017, 140(6): 1324-1330.
[18] Zhao L H,Liu X,Yan H X. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma[J]. Nat Commun, 2016, 7: 12992.
[19] Dratwa M,Wysoczanska B,Lacina P. TERT-Regulation and roles in cancer formation[J]. Front Immunol, 2020, 11: 589929.
[20] Zapatka M,Borozan I,Brewer D S. The landscape of viral associations in human cancers[J]. Nat Genet, 2020, 52(3): 320-330.
[21] Froimchuk E,Jang Y,Ge K. Histone H3 lysine 4 methyltransferase KMT2D[J]. Gene, 2017, 627: 337-342.
[22] Turner N C,Liu Y,Zhu Z. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer[J]. J Clin Oncol, 2019, 37(14): 1169-1178.
[23] Aziz K,Limzerwala J F,Sturmlechner I. Ccne1 overexpression causes chromosome instability in liver cells and liver tumor development in mice[J]. Gastroenterology, 2019, 157(1): 210-226. e212.
[24] Xu H,George E,Kinose Y. CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models[J]. Cell Rep Med, 2021, 2(9): 100394.
[25] Yang R,Xing L,Zheng X. The circRNA circAGFG1 acts as a sponge of miR-195-5p to promote triple-negative breast cancer progression through regulating CCNE1 expression[J]. Mol Cancer, 2019, 18(1): 4.
[26] Wang H,Zhang J,Li H. FN1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers[J]. Front Oncol, 2022, 12: 918719.
[27] Sung W-K,Zheng H,Li S. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma[J]. Nature Genetics, 2012, 44(7): 765-769.
[28] 蒋素贞,杨紫伟,李韦杰. 原发性肝细胞癌中HBV DNA整合位点分析[J]. 中国医学前沿杂志(电子版), 2011, 3(01): 56-60.
[29] Li M,Shen Y,Chen Y. Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma[J]. Int J Cancer, 2020, 147(8): 2199-2209.
[30] 齐鲁楠,陈圆圆,陈祖舜. 广西地区乙肝病毒/黄曲霉毒素B_1双暴露相关性肝细胞性肝癌微阵列比较基因组学的研究[J]. 中国癌症防治杂志, 2013, 5(3): 201-210.
[31] Tamori A,Yamanishi Y,Kawashima S. Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA[J]. Clin Cancer Res, 2005, 11(16): 5821-5826.
[32] Alvarez E G,Demeulemeester J,Otero P. Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture[J]. Nat Commun, 2021, 12(1): 6910.
[33] Mason W S,Jilbert A R,Litwin S. Hepatitis B virus DNA integration and clonal expansion of hepatocytes in the chronically infected liver[J]. Viruses, 2021, 13(2):210.
[34] Decorsiere A,Mueller H,van Breugel P C. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor[J]. Nature, 2016, 531(7594): 386-389.
[35] Sekiba K,Otsuka M,Ohno M. Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction[J]. Cell Mol Gastroenterol Hepatol, 2019, 7(2): 297-312.
[36] Chen L,Hu L,Li L. Dysregulation of beta-catenin by hepatitis B virus X protein in HBV-infected human hepatocellular carcinomas[J]. Front Med China, 2010, 4(4): 399-411.
[37] Yang W Y,Rao P S,Luo Y C. Omics-based investigation of diet-induced obesity synergized with HBx, Src, and p53 mutation accelerating hepatocarcinogenesis in zebrafish model[J]. Cancers (Basel), 2019, 11(12):1899.
[38] Hai H,Tamori A,Kawada N. Role of hepatitis B virus DNA integration in human hepatocarcinogenesis[J]. World J Gastroenterol, 2014, 20(20): 6236-6243.
[39] Jung S Y,Kim Y J. C-terminal region of HBx is crucial for mitochondrial DNA damage[J]. Cancer Lett, 2013, 331(1): 76-83.
[40] Zhang Y,Yan Q,Gong L. C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism[J]. Oncogene, 2021, 40(6): 1147-1161.
[41] Mao X,Tey S K,Ko F C F. C-terminal truncated HBx protein activates caveolin-1/LRP6/beta-catenin/FRMD5 axis in promoting hepatocarcinogenesis[J]. Cancer Lett, 2019, 444: 60-69.
[42] Tu T,Zhang H,Urban S. Hepatitis B virus DNA integration: in vitro models for investigating viral pathogenesis and persistence[J]. Viruses, 2021, 13(2):180.
[43] Lau C C,Sun T,Ching A K. Viral-human chimeric transcript predisposes risk to liver cancer development and progression[J]. Cancer Cell, 2014, 25(3): 335-349.
[44] Tu T,Budzinska M A,Shackel N A. HBV DNA integration: molecular mechanisms and clinical implications[J]. Viruses, 2017, 9(4):75.
[45] Cao Q,Imbeaud S,Datta S. Authors' response: virus-host interactions in HBV-related hepatocellular carcinoma: more to be revealed?[J]. Gut, 2015, 64(5): 853-854.
[46] Nault J C,Ningarhari M,Rebouissou S. The role of telomeres and telomerase in cirrhosis and liver cancer[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(9): 544-558.
[47] Okamoto K,Seimiya H. Revisiting telomere shortening in cancer[J]. Cells, 2019, 8(2):107.
[48] In der Stroth L,Tharehalli U,Gunes C. Telomeres and telomerase in the development of liver cancer[J]. Cancers (Basel), 2020, 12(8):2048.
[49] Li C L,Li C Y,Lin Y Y. Androgen receptor enhances hepatic telomerase reverse transcriptase gene transcription after hepatitis B virus integration or point mutation in promoter region[J]. Hepatology, 2019, 69(2): 498-512.
[50] Wang S H,Yeh S H,Lin W H. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B[J]. Hepatology, 2009, 50(5): 1392-1402.
[51] Wang S H,Yeh S H,Lin W H. Estrogen receptor alpha represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4alpha[J]. Gastroenterology, 2012, 142(4): 989-998. e984.
[52] Grudda T,Hwang H S,Taddese M. Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment[J]. J Clin Invest, 2022, 132(18):e161818.
[53] Rehermann B,Bertoletti A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections[J]. Hepatology, 2015, 61(2): 712-721.
[54] Ye J,Chen J. Interferon and hepatitis B: current and future perspectives[J]. Front Immunol, 2021, 12: 733364.
[55] Wang Y X,Niklasch M,Liu T. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication[J]. J Hepatol, 2020, 72(5): 865-876.
[56] Shao Y,Su L,Hao R. Advances on molecular mechanism of hepatitis B virus-induced hepatocellular carcinoma[J]. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2021, 50(1): 113-122.
[57] Yang Y C,Yang H C. Recent progress and future prospective in HBV cure by CRISPR/Cas[J]. Viruses, 2021, 14(1):4.